Loading financial data...

REVELATION BIOSCIENCES, INC. (REVBW) Financial Statements | Global Financial Data

REVELATION BIOSCIENCES, INC.

REVBWSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1810560

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Research and Development Expense	$3.5M	$4.1M	$5.4M	$6.9M	—
Operating Expenses	$8.0M	$8.7M	$10.9M	$12.0M	$145.5K
Operating Income (Loss)	-$8.0M	-$8.7M	-$10.9M	-$12.0M	—
Interest Expense	—	—	—	—	$41.8K
Nonoperating Income (Expense)	-$7.1M	$8.5M	$35.0K	-$36.4K	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	—	—	—	—	—
Income Tax Expense (Benefit)	$0.00	$0.00	$0.00	$0.00	—
Net Income (Loss) Attributable to Parent	-$15.0M	-$120.3K	-$10.8M	-$12.0M	-$1.6M
Earnings Per Share, Basic	-$1.1K	-$8.44	-$149.20	-$42.50	-$0.68
Earnings Per Share, Diluted	-$1.1K	-$8.44	-$149.20	-$42.50	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$6.6M	$12.2M	$5.5M	$2.0M	$74.2M
Assets, Current	$6.6M	$12.1M	$5.4M	$1.9M	$651.3K
Cash and Cash Equivalents, at Carrying Value	$6.5M	$12.0M	$5.3M	$1.3M	$11.7K
Liabilities	$1.9M	$5.6M	$4.5M	$2.1M	$6.3M
Liabilities, Current	$1.9M	$5.6M	$4.5M	$2.1M	$3.4M
Accounts Payable, Current	$783.6K	$1.4M	$554.2K	$596.3K	$33.8K
Stockholders' Equity Attributable to Parent	$6.6M	$1.1M	-$99.5K	$3.4M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$18.3M	-$7.3M	-$11.2M	-$11.1M	-$216.7K
Net Cash Provided by (Used in) Investing Activities	-$19.2K	-$19.2K	—	-$132.0K	-$74.0M
Net Cash Provided by (Used in) Financing Activities	$12.8M	$14.0M	$15.2M	$8.0M	$74.3M
Payments to Acquire Property, Plant, and Equipment	$19.2K	$19.2K	—	$132.0K	—
Payments for Repurchase of Common Stock	—	—	—	$35.5M	$35.5M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)